Vaxart announces a successful Phase 2 influenza challenge study - and nothing happens! In theory, 40% of any rise should come onto AVIRs SP, but they got zero.
Amazing.
I think these guys have burnt all their fund manager bridges.
BTA Price at posting:
57.0¢ Sentiment: Hold Disclosure: Held
